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Introduction {#slct201703052-sec-0001}
============

Nucleoside analogues represent a broad class of small molecule compounds extensively studied as promising broad‐spectrum antivirals.[1](#slct201703052-bib-0001){ref-type="ref"} Compounds with nucleoside scaffold are implied to interfere with nucleic acid processing machinery, suppressing viral replication. This strategy is used in the treatment of hepatitis B virus (HBV, DNA virus with reverse transcription, *Hepadnaviridae* family) or human immunodeficiency virus (HIV, RNA virus with reverse transcription, *Retroviridae* family) infections.[1](#slct201703052-bib-0001){ref-type="ref"} It seems especially attractive for viruses with RNA genomes, replicated by viral RNA‐dependent RNA polymerases. These enzymes are unique for viruses, thus a superior selectivity with less side effects is achievable for nucleoside‐based antivirals targeting these enzymes. On the other hand, viral RNA polymerases are rather similar to each other, and it is highly possible that the same compound may inhibit several of them. Despite numerous nucleoside analogues being available, spectrum of their antiviral activity remains poorly studied, with most compounds non‐systematically tested against one or two viruses.

Enteroviruses are small non‐enveloped RNA viruses widely circulating all over the world and causing diseases mostly in children. The need for small molecule drugs against enteroviruses is justified by diversity of these viruses and ability to cause outbreaks, the range of syndromes they cause and increasing number of neuroinfections with severe CNS damage, such as poliomyelitis, encephalitis, aseptic meningitis, and acute flaccid myelitis.[2](#slct201703052-bib-0002){ref-type="ref"} High variability of enteroviral antigens prohibits development of a universal anti‐enteroviral vaccine, and more conserved replication machinery opens the possibility to create pan‐enteroviral drugs.[2](#slct201703052-bib-0002){ref-type="ref"} Several dozens of enterovirus serotypes are grouped into the genus *Enterovirus*: species *Enterovirus A* to *D* and *Rhinovirus A* to *C* include human pathogens. According to our searches in ChEMBL database, containing annotated biological activity data for more than 1.3 million compounds,[3](#slct201703052-bib-0003){ref-type="ref"} 2406 different compounds were tested against at least one enterovirus, but only 32 of them were simultaneously assessed against *Enterovirus A*, *Enterovirus B*, and *Enterovirus C* species representatives. These 32 compounds interact with capsid proteins,[4](#slct201703052-bib-0004){ref-type="ref"} host targets,[5](#slct201703052-bib-0005){ref-type="ref"} or 3C protease[6](#slct201703052-bib-0006){ref-type="ref"} and do not contain nucleoside‐like scaffolds. Although literature coverage by ChEMBL is not comprehensive, systematic studies of nucleoside antiviral activity against different enteroviruses are sporadic and do not show a consistent picture.

Nucleosides with hydrophobic substituents in nucleobase moiety were previously shown to be efficient inhibitors of enterovirus A71 (*Enterovirus A*) reproduction, but most of them did not inhibit reproduction of polioviruses (*Enterovirus C*) nor coxsackievirus B3 and echovirus 11 (*Enterovirus B*).[7](#slct201703052-bib-0007){ref-type="ref"} We have also shown that some of these compounds may inhibit the reproduction of tick‐borne encephalitis virus (TBEV),[8](#slct201703052-bib-0008){ref-type="ref"} which is an enveloped RNA arbovirus endemic for the Northern Eurasia. Transmitted by infected ticks, this virus may cause severe neurological symptoms in a form of encephalitis or meningoencephalitis, eventually leading to death or serious disabilities. Over ten thousand cases are registered annually despite the availability of vaccines, and small molecule compounds comprise a promising and highly expected treatment option.[9](#slct201703052-bib-0009){ref-type="ref"}

To extend our knowledge on the spectrum of antiviral activity of nucleoside analogues with hydrophobic substituents in the nucleobases, we performed profiling of antiviral activity of ten diverse nucleoside analogues and derivatives against TBEV strain Absettarov (genus *Flavivirus*, family *Flaviviridae*) and a panel of enterovirus isolates of 2012--2014, representing three major species of genus *Enterovirus* (family *Picornaviridae*, order *Picornavirales*): *Enterovirus A* (enterovirus A71, coxsackievirus A16), *Enterovirus B* (coxsackieviruses B1 and A9, echoviruses 6 and 30), *Enterovirus C* (strain Sabin 1 poliovirus type 1). We found that in most cases the antiviral activity appeared only against *Enterovirus A* species representatives.

Results and Discussion {#slct201703052-sec-0002}
======================

We selected for our study ten nucleoside analogues with modifications in the nucleic base or sugar moiety presented in the Table [1](#slct201703052-tbl-0001){ref-type="table"}. Compounds **1--3** are commonly known nucleoside analogs.[10](#slct201703052-bib-0010){ref-type="ref"} Compounds **6--10** were described by us earlier,[11](#slct201703052-bib-0011){ref-type="ref"} whereas 2‐thio‐5‐modified‐6‐azauridines **4** and **5** were synthesized for the first time.

###### 

Structures, toxicity, and antiviral activity of nucleoside analogues.

+----------------------------------------------------------------------------------------------------------+--------------------------+-------------------------+--------------------+-----------------------------------------+
| Structure                                                                                                | PEK CC~50~ \[μM\]^\[a\]^ | RD CC~50~ \[μM\]^\[b\]^ | TBEV EC~50~ \[μM\] | EV EC~50~ \[μM\]^\[c\]^                 |
+==========================================================================================================+==========================+=========================+====================+=========================================+
| ![](SLCT-3-2321-g002.jpg "image")                                                                        | \>50 (24 h);             | \>125 (24 h);           | \> 50              | \> 125 (EVA71, CVB1, PV1)               |
|                                                                                                          |                          |                         |                    |                                         |
| 1‐(β‐[d]{.smallcaps}‐ribofuranosyl)isocarbostyryl (**1**)                                                | \>50 (7 d)               | 73 (7 d)                |                    |                                         |
+----------------------------------------------------------------------------------------------------------+--------------------------+-------------------------+--------------------+-----------------------------------------+
| ![](SLCT-3-2321-g003.jpg "image")                                                                        | \>50 (24 h);             | 73 (24 h);              | \> 50              | \> 125 (EVA71, CVB1, PV1)               |
|                                                                                                          |                          |                         |                    |                                         |
| 2'‐Amino‐2'‐deoxyadenosine (**2**)                                                                       | 26 (7 d)                 | 20 (7 d)                |                    |                                         |
+----------------------------------------------------------------------------------------------------------+--------------------------+-------------------------+--------------------+-----------------------------------------+
| ![](SLCT-3-2321-g004.jpg "image")                                                                        | \>50 (24 h);             | 73 (24 h);              | \> 50              | 28±13 (EVA71);                          |
|                                                                                                          |                          |                         |                    |                                         |
| *N* ^4^‐Hydroxycytidine (**3**)                                                                          | \>50 (7 d)               | 73 (7 d)                |                    | 5.41 (CVA16);                           |
|                                                                                                          |                          |                         |                    |                                         |
|                                                                                                          |                          |                         |                    | 18.41 (CVA9);                           |
|                                                                                                          |                          |                         |                    |                                         |
|                                                                                                          |                          |                         |                    | 7.74 (CVB1);                            |
|                                                                                                          |                          |                         |                    |                                         |
|                                                                                                          |                          |                         |                    | 18.41 (ECHO30);                         |
|                                                                                                          |                          |                         |                    |                                         |
|                                                                                                          |                          |                         |                    | 73.66 (ECHO6);                          |
|                                                                                                          |                          |                         |                    |                                         |
|                                                                                                          |                          |                         |                    | 36.83 (PV1)                             |
+----------------------------------------------------------------------------------------------------------+--------------------------+-------------------------+--------------------+-----------------------------------------+
| ![](SLCT-3-2321-g005.jpg "image")                                                                        | ND^a^                    | 104 (24 h);             | \> 50              | \> 125 (EVA71, CVB1, PV1)               |
|                                                                                                          |                          |                         |                    |                                         |
| 2‐Thio‐5‐(*tert*‐butyl)‐6‐azauridine (**4**)                                                             |                          | 104 (7 d)               |                    |                                         |
+----------------------------------------------------------------------------------------------------------+--------------------------+-------------------------+--------------------+-----------------------------------------+
| ![](SLCT-3-2321-g006.jpg "image")                                                                        | ND                       | \>125 (24 h);           | \> 50              | \> 125 (EVA71, CVB1, PV1)               |
|                                                                                                          |                          |                         |                    |                                         |
| 2‐Thio‐5‐phenyl‐6‐azauridine (**5**)                                                                     |                          | \>125 (7 d)             |                    |                                         |
+----------------------------------------------------------------------------------------------------------+--------------------------+-------------------------+--------------------+-----------------------------------------+
| ![](SLCT-3-2321-g007.jpg "image")                                                                        | ND                       | \>125 (24 h);           | \> 50              | \> 125 (EVA71, CVB1, PV1)               |
|                                                                                                          |                          |                         |                    |                                         |
| 3‐(β‐[d]{.smallcaps}‐Ribofuranosyl)‐6‐hydroxymethyl‐2,3‐dihydrofurano\[2, 3‐*d*\]pyrimidin‐2‐one (**6**) |                          | \>125 (7 d)             |                    |                                         |
+----------------------------------------------------------------------------------------------------------+--------------------------+-------------------------+--------------------+-----------------------------------------+
| ![](SLCT-3-2321-g008.jpg "image")                                                                        | ND                       | 73 (24 h);              | \> 50              | 18±12 (EVA71);                          |
|                                                                                                          |                          |                         |                    |                                         |
| 3‐(β‐[d]{.smallcaps}‐Ribofuranosyl)‐6‐pentyl‐2,3‐dihydrofurano\[2, 3‐*d*\]pyrimidin‐2‐one (**7**)        |                          | 73 (7 d)                |                    | 4.6 (CVA16);                            |
|                                                                                                          |                          |                         |                    |                                         |
|                                                                                                          |                          |                         |                    | \> 125 (CVA9, CVB1, ECHO30, ECHO6, PV1) |
+----------------------------------------------------------------------------------------------------------+--------------------------+-------------------------+--------------------+-----------------------------------------+
| ![](SLCT-3-2321-g009.jpg "image")                                                                        | ND                       | 73 (24 h);              | \> 50              | 16±9 (EVA71);                           |
|                                                                                                          |                          |                         |                    |                                         |
| 3‐(β‐[d]{.smallcaps}‐Ribofuranosyl)‐6‐hexyl‐2,3‐dihydrofurano\[2, 3‐*d*\]pyrimidin‐2‐one (**8**)         |                          | 36 (7 d)                |                    | 3.26 (CVA16);                           |
|                                                                                                          |                          |                         |                    |                                         |
|                                                                                                          |                          |                         |                    | \> 125 (CVA9, CVB1, ECHO30, ECHO6, PV1) |
+----------------------------------------------------------------------------------------------------------+--------------------------+-------------------------+--------------------+-----------------------------------------+
| ![](SLCT-3-2321-g010.jpg "image")                                                                        | \>50 (24 h);             | \>125 (24 h);           | \> 50              | \> 125 (EVA71, CVB1, PV1)               |
|                                                                                                          |                          |                         |                    |                                         |
| 3‐(β‐[d]{.smallcaps}‐Ribofuranosyl)‐6‐decyl‐2,3‐dihydrofurano\[2, 3‐*d*\]pyrimidin‐2‐one (**9**)         | \>50 (7 d)               | \>125 (7 d)             |                    |                                         |
+----------------------------------------------------------------------------------------------------------+--------------------------+-------------------------+--------------------+-----------------------------------------+
| ![](SLCT-3-2321-g011.jpg "image")                                                                        | \>50 (24 h);             | 73 (24 h);              | 9.4±0.4            | \> 73 (EVA71, CVB1, PV1)                |
|                                                                                                          |                          |                         |                    |                                         |
| 5‐(Tetradec‐1‐yn‐1‐yl)‐uridine (**10**)                                                                  | \>50 (7 d)               | 20 (7 d)                |                    |                                         |
+----------------------------------------------------------------------------------------------------------+--------------------------+-------------------------+--------------------+-----------------------------------------+
| *N* ^6^‐Benzyladenosine (**12 a**)                                                                       | ND                       | 9.21 (24 h);            | \> 50              | 2.5±0.2 (EVA71);                        |
|                                                                                                          |                          |                         |                    |                                         |
|                                                                                                          |                          | 9.21 (7 d)              |                    | 0.92±0.24 (CVA16);                      |
|                                                                                                          |                          |                         |                    |                                         |
|                                                                                                          |                          |                         |                    | 7.75±3.15 (CVB1);                       |
|                                                                                                          |                          |                         |                    |                                         |
|                                                                                                          |                          |                         |                    | 11.1±1.9 (ECHO30);                      |
|                                                                                                          |                          |                         |                    |                                         |
|                                                                                                          |                          |                         |                    | 10.15±0.95 (PV1)                        |
+----------------------------------------------------------------------------------------------------------+--------------------------+-------------------------+--------------------+-----------------------------------------+
| dUY11 (**11 a**)                                                                                         | \>50 (24 h);             | ND                      | 0.024±0.013^\[e\]^ | ND                                      |
|                                                                                                          |                          |                         |                    |                                         |
|                                                                                                          | \>50 (7 d)^\[e\]^        |                         |                    |                                         |
+----------------------------------------------------------------------------------------------------------+--------------------------+-------------------------+--------------------+-----------------------------------------+

\[a\] PEK, porcine embryo kidney cells. \[b\] RD, rhabdomyosarcoma cells. \[c\] EV, enteroviruses. \[d\] ND, not determined. \[e\] Data from ref. 12.
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Antiviral activity and cytotoxicity were determined using previously described methods for TBEV (plaque reduction test[12](#slct201703052-bib-0012){ref-type="ref"}) and enteroviruses (cytopathic effect inhibition test[13](#slct201703052-bib-0013){ref-type="ref"}). Enterovirus activity screening was performed against enterovirus A71 (EVA71), coxsackievirus B1 (CVB1), and poliovirus (PV1); active compounds were additionally assessed against the remaining viruses. All tested compounds showed acceptable levels of acute (24 h) and chronic (7 d) cytotoxicity (Table [1](#slct201703052-tbl-0001){ref-type="table"}). Fifty % effective concentrations (EC~50~) of the compounds are given in Table [1](#slct201703052-tbl-0001){ref-type="table"}. *N* ^6^‐Benzyladenosine was used as the positive control for anti‐enterovirus activity, and previously published data for dUY11, obtained according to the same protocol, served as TBEV inhibition positive control.[12](#slct201703052-bib-0012){ref-type="ref"}

Compounds **1**, **2**, **4**, and **5** did not show any antiviral activity in the tests. For compound **2** (2′‐amino‐2′‐deoxyadenosine, 2‐AA) this observation is in line with the previous study,[14](#slct201703052-bib-0014){ref-type="ref"} where replication inhibition was observed for measles virus, but not for echovirus 7, nor herpes simplex virus 2, vesicular stomatitis virus, and BK virus. Compound **3**, *N* ^4^‐hydroxycytidine (NHC), on the contrary, revealed itself as a pan‐enterovirus reproduction inhibitor with a preference for coxsackieviruses independently of the enterovirus species assignment. Nevertheless, this compound did not inhibit TBEV reproduction at 50 μM concentration. In the previous studies NHC was shown to inhibit the replication of viruses with various genomes and replication cycles: (+)ssRNA genomic bovine viral diarrhea (BVDV) and hepatitis C (HCV) viruses, both belonging to *Flaviviridae* family,[15](#slct201703052-bib-0015){ref-type="ref"} severe acute respiratory syndrome‐associated coronavirus,[16](#slct201703052-bib-0016){ref-type="ref"} norovirus,[17](#slct201703052-bib-0017){ref-type="ref"} chikungunya virus;[18](#slct201703052-bib-0018){ref-type="ref"} (‐)ssRNA genomic Ebola virus,[19](#slct201703052-bib-0019){ref-type="ref"} and DNA genomic vaccinia, monkeypox, and cowpox viruses (family *Poxviridae*).[20](#slct201703052-bib-0020){ref-type="ref"} However, it is not active against HIV‐1, hepatitis B virus, and herpes simplex viruses.[15](#slct201703052-bib-0015){ref-type="ref"} Such a profile of antiviral activity suggests that this compound may target host proteins, as well as viral ones. This compound is also a well‐known mutagen mimicking cytidine,[10c](#slct201703052-bib-0010c){ref-type="ref"} and fast replicating viruses may be more susceptible to its incorporation into genome than cells.

Time‐of‐addition studies against EVA71 and PV1 were performed for NHC to further clarify its mechanism of action. Cells were incubated with NHC or DMSO for 1 h, then virus pre‐incubated with NHC or DMSO was added and left for 1 h for sorption and entry, and then cultural medium with NHC or DMSO was added. Virus was harvested after a single replication cycle and total virus yields were determined. The schemes of the experiment and results are given in Table [2](#slct201703052-tbl-0002){ref-type="table"}. Significant reduction of virus yields in the schemes D, E, and F suggests that NHC targets the stages of reproduction that occur after entry, i. e., replication and/or virion assembly, and does not prevent viral entry. This target stage is expected for nucleoside analogues.

###### 

Time‐of‐addition assessment for NHC with enteroviruses.

  Experiment Scheme   Supposed Target        Addition of components   Virus Yield (logTCID~50~/mL)                      
  ------------------- ---------------------- ------------------------ ------------------------------ ------ ----------- -----------
  A                   Control                DMSO                     DMSO + virus                   DMSO   4.5±0.18    4.0±0.53
  B                   Cell                   NHC                      DMSO + virus                   DMSO   4.13±0.18   3.44±0.09
  C                   Virion                 DMSO                     NHC + virus                    DMSO   4.19±0.27   3.63±0.35
  D                   After entry            DMSO                     DMSO + virus                   NHC    2.5±0.01    1.44±0.09
  E                   Cell & after entry     NHC                      DMSO + virus                   NHC    2.5±0.01    1.13±0.53
  F                   Virion & after entry   DMSO                     NHC + virus                    NHC    2.75±0.35   1.75±0.35
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Furano\[2, 3‐*d*\]pyrimidine nucleosides **6**‐**9** and their synthetic precursor analogue **10** [11](#slct201703052-bib-0011){ref-type="ref"} showed a specific pattern of antiviral activity. These compounds were previously assessed for inhibition of reproduction of HCV and BVDV (RNA viruses, *Flaviviridae* family).[9](#slct201703052-bib-0009){ref-type="ref"} The only active compound in these assays was **9**, with EC~50~ of 1.9 μM against BVDV and moderate HCV inhibition at 100 μM, without inhibition of RNA‐dependent RNA polymerase NS5B and RNA helicase NS3. Analogues with alkyn‐1‐yl tails were tested against varicella zoster virus and human cytomegalovirus (DNA viruses, *Herpesvirales* order), and the most potent ones had C10 and C12 tails.[21](#slct201703052-bib-0021){ref-type="ref"} For non‐enveloped RNA genomic enteroviruses an optimal chain length for alkyl also exists: compounds **7** and **8** with C5 and C6 alkyls are the only active ones, and elongation (**9**) or removal (**6**) of the chain lead to inactivity. This pattern also suggests that activity is unlikely to be attributed to the detergent properties of the molecule, given that only viruses belonging to *Enterovirus A* species, EVA71 and CVA16, are susceptible to these compounds. Such species selectivity profile was also observed for other classes of hydrophobic nucleosides, e. g., *N* ^6^‐substituted adenosines \[A. A. Orlov, V. E. Oslovsky, S. N. Mikhailov, L. I. Kozlovskaya, D. I. Osolodkin, manuscript in preparation\]. This selectivity may be attributed to sequence differences of replication machinery proteins on the species level.[22](#slct201703052-bib-0022){ref-type="ref"}

Compared with *N* ^6^‐benzyladenosine, which had been earlier shown to efficiently inhibit reproduction of enteroviruses,[7](#slct201703052-bib-0007){ref-type="ref"} compounds **3**, **7**, and **8** show a much more acceptable toxicity level. Whereas the CC~50~/EC~50~ ratio for *N* ^6^‐benzyladenosine in our hands is no larger than 10 (observed for CVA16), for the same virus this ratio is 16 for **7** and 22 for **8**. It is worth noting that the toxicity level itself is much lower for furano\[2, 3‐*d*\]pyrimidine nucleosides than for *N* ^6^‐benzyladenosine, and it opens the way for the further design of more potent congeners keeping the same low toxicity.

The only compound that suppressed reproduction of enveloped RNA genomic TBEV was **10**. Structure of this compound falls into the same line with so‐called rigid amphipathic fusion inhibitors (RAFI, **11**, Figure [1](#slct201703052-fig-0001){ref-type="fig"}), typical representatives of which differ from **10** in hydrophobic moiety: instead of a long alkyl, an ethynyl connects a perylenyl moiety to uracil in RAFIs.[12](#slct201703052-bib-0012){ref-type="ref"},[23](#slct201703052-bib-0023){ref-type="ref"} RAFI mechanism of action is supposed to realize through the incorporation of the perylene moiety into the viral membrane leading to membrane fusion prevention due to the shape restrictions or singlet oxygen production.[24](#slct201703052-bib-0024){ref-type="ref"} Incorporation of a flexible linker between perylene and nucleoside (**11 b**) instead of ethynyl (**11 a**) in our previous studies led to EC~50~ drop from two‐digit nanomolar values to micromolar ones.[12](#slct201703052-bib-0012){ref-type="ref"} Change or even removal of nucleoside moiety does not impair activity of RAFIs, but substitution of perylene by phenyl (**11 c**) or 2‐pyrenyl (**11 d**) does.[23](#slct201703052-bib-0023){ref-type="ref"} Compound **10** does not contain a perylene core, bearing a C12 *n*‐alkyl instead, and it shows slightly lower activity than RAFI with the flexible linker, justifying again the importance of perylene fragment. Activity profile of compounds **7--9** against TBEV, HCV, and BVDV (all *Flaviviridae* family), suggests that the ability of a compound to incorporate into the viral membrane does not guarantee antiviral activity of the compound, and the geometry of nucleoside head is important for alkylated nucleosides. Similar peculiarities were already observed for anti‐TBEV activity of *N* ^6^‐substituted adenosines with hydrophobic substituents,[8](#slct201703052-bib-0008){ref-type="ref"} where introduction of alkyls did not lead to the inhibition of viral reproduction, whereas large aryls (**12**) positively affected the activity.

![Anti‐TBEV activity of nucleosides with hydrophobic substituents.[8](#slct201703052-bib-0008){ref-type="ref"},[12](#slct201703052-bib-0012){ref-type="ref"},[23](#slct201703052-bib-0023){ref-type="ref"}](SLCT-3-2321-g001){#slct201703052-fig-0001}

Conclusions {#slct201703052-sec-0003}
===========

Screening of antiviral activity of diverse nucleoside analogues revealed new data on activity of *N* ^4^‐hydroxycytidine, which showed pan‐enterovirus inhibition without effect on TBEV, and furano\[2, 3‐*d*\]pyrimidine nucleosides with long alkyl tails, selectively inhibiting replication of *Enterovirus A* species members. These data improved understanding of structure‐activity relationships of congeneric series, offering new opportunities in the design of broad‐spectrum antivirals.
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Experimental Section is available as Supporting Information, containing details of compound preparation and biological experiments.
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